Development and specification of physiologically based pharmacokinetic models for use in risk assessment.
about
Advances in inhalation dosimetry models and methods for occupational risk assessment and exposure limit derivationAnimal-Free Chemical Safety AssessmentMathematical model of uptake and metabolism of arsenic(III) in human hepatocytes - Incorporation of cellular antioxidant response and threshold-dependent behaviorA Workflow for Global Sensitivity Analysis of PBPK Models.A physiologically based pharmacokinetic model for capreomycin.The application of global sensitivity analysis in the development of a physiologically based pharmacokinetic model for m-xylene and ethanol co-exposure in humans.A physiologically based pharmacokinetic model of rifampin in mice.The future of toxicity testing.Challenges in the application of quantitative approaches in risk assessment: a case study with di-(2-ethylhexyl)phthalate.An evaluation of the latest in vitro tools for drug metabolism studies.An introduction to physiologically-based pharmacokinetic models.In vivo effects of naproxen, salicylic acid, and valproic acid on the pharmacokinetics of trichloroethylene and metabolites in rats.A physiologically based pharmacokinetic model for chickens exposed to feed supplemented with monensin during their lifetime.Physiologically Based Pharmacokinetic (PBPK) Model for Biodistribution of Radiolabeled Peptides in Patients with Neuroendocrine Tumours.Modeling Pharmacokinetics.Computational toxicology: realizing the promise of the toxicity testing in the 21st century.Sensitivity analysis on a physiologically-based pharmacokinetic and pharmacodynamic model for diisopropylfluorophosphate-induced toxicity in mice and rats.Tutorial on physiologically based kinetic modeling in molecular nutrition and food research.Calibration and validation of a physiologically based model for soman intoxication in the rat, marmoset, guinea pig and pig.A hybrid CFD-PBPK model for naphthalene in rat and human with IVIVE for nasal tissue metabolism and cross-species dosimetry.Scientific Opinion on the hazard assessment of endocrine disruptors: Scientific criteria for identification of endocrine disruptors and appropriateness of existing test methods for assessing effects mediated by these substances on human health and...Modern methodologies and tools for human hazard assessment of chemicalsChallenges Associated with Applying Physiologically Based Pharmacokinetic Modeling for Public Health Decision-Making.POPs and Human Health Risk AssessmentModeling Kinetic Interactions of Chemical Mixtures
P2860
Q23912442-EFB0EF45-008E-4DAA-88C1-F32EA329FEE3Q26738977-77D752D6-56FA-4A09-A753-96296DEBBF39Q27499027-0E29459B-B554-484A-B8BA-AA4C393F583AQ35084469-8FA72FB5-25CA-4E55-A5D6-36A4B4E3A4F3Q35689199-CAB9A531-C37A-4BAC-96F3-69F2F85E7C96Q35796328-368D800F-7E25-4991-9986-5C1F9784DC0DQ36757635-2930FC10-6A55-4D30-9D1B-99E37781ECC6Q37767386-FA5D4137-A7CE-4502-8D4D-2004E5DAF86BQ37916566-BAAC27A5-8638-412C-A751-BC07EFE26387Q38160881-B8710F35-4BFE-492B-BFA0-988D4B0A9170Q38934455-9CB9523D-E5ED-4493-BF57-15BD2AAA99E5Q38999765-440AD4B7-35E8-4D3C-B331-ADB32E257127Q39108918-EC7C3D8B-883E-44C1-8820-10272200519BQ39607591-3249E3DD-586B-41F1-999D-B790A6A67E13Q39677925-313CFD44-E597-4374-9880-B0D06872F633Q42540572-6976C822-D830-443B-9AD6-86C2D9CA955BQ43269698-2C4A1A43-E2CA-4ECF-B980-20BAC34B61A5Q43778218-ABD460C1-906D-47B1-8E43-8BFF594E5677Q44403400-ACE30F96-11CD-40E3-B2F8-DABF0BDF9AFBQ46914722-2A7383A1-6389-4AEF-B385-E6285C01EB79Q47153078-A77DEBEB-AF91-49A5-88CC-3BEC92B9A4A7Q47154406-BBC6E75D-AEC7-49CC-837E-57EF17A06281Q49551649-069CC1EC-C7B8-4856-9312-7653A9EF2101Q55893642-4D38A624-FA76-478B-9BC4-C929DC51AA28Q57382869-1525DAFE-CD90-45B3-84FD-CC1573940CF6
P2860
Development and specification of physiologically based pharmacokinetic models for use in risk assessment.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Development and specification ...... ls for use in risk assessment.
@en
Development and specification ...... ls for use in risk assessment.
@nl
type
label
Development and specification ...... ls for use in risk assessment.
@en
Development and specification ...... ls for use in risk assessment.
@nl
prefLabel
Development and specification ...... ls for use in risk assessment.
@en
Development and specification ...... ls for use in risk assessment.
@nl
P1476
Development and specification ...... ls for use in risk assessment.
@en
P2093
Harvey J Clewell
Rebecca A Clewell
P304
P356
10.1016/J.YRTPH.2007.10.012
P407
P577
2007-11-06T00:00:00Z